Comparative Pharmacology
Head-to-head clinical analysis: GENOPTIC versus LOTEPREDNOL ETABONATE AND TOBRAMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENOPTIC versus LOTEPREDNOL ETABONATE AND TOBRAMYCIN.
GENOPTIC vs LOTEPREDNOL ETABONATE AND TOBRAMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Genoptic (gentamicin ophthalmic) is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins.
Loteprednol etabonate is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis; tobramycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis.
Instill 1-2 drops into affected eye(s) every 4-6 hours; for severe infections, every 1-2 hours initially, then reduce frequency as improvement occurs.
1-2 drops into affected eye(s) every 4-6 hours; in severe cases, may be given every 1-2 hours initially.
None Documented
None Documented
2-3 hours (prolonged in renal impairment to 18-24 hours); in neonates, 3-8 hours.
Loteprednol etabonate: ~2.8 hours (ocular); Tobramycin: ~2-3 hours (systemic, prolonged in renal impairment)
Primarily renal (70-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <5%.
Loteprednol etabonate: 75% renal, 20% fecal; Tobramycin: >90% renal as unchanged drug via glomerular filtration
Category C
Category D/X
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic